Hongrun Construction established a commercial management company in Wuxi. According to the enterprise search APP, Wuxi Hongrun Commercial Management Co., Ltd. was recently established. The legal representative is Jin Zhenjun, with a registered capital of 1 million yuan. Its business scope includes: commercial complex management services; Property management; Real estate broker, etc. Enterprise investigation shows that the company is wholly owned by Hongrun Construction.In the exchange market, the national debt rose the most, with "National Debt 2404" rising more than 4%, "National Debt 23", "Special Country 24 03" and "Special Country 24 01" rising nearly 1%.Chief Cabinet Secretary of Japan: Short-term data show that enterprises have a strong willingness to invest.
Shanghai Securities: The pharmaceutical and bio-industry is expected to further repair its performance and valuation. The Shanghai Securities Research Report pointed out that with the support of policies and the adjustment of the internal structure of the industry, the pharmaceutical and bio-industry is expected to further repair its performance and valuation. It is suggested to pay attention to five directions: 1) Innovative drugs (with strong national policy support, the payment terminal is expected to further improve and go to sea to occupy the global market); 2)CXO (the negative impact of the biosafety bill event has been eliminated, and the demand for orders in the superimposed interest rate reduction cycle has increased, which is expected to usher in a double repair of performance and valuation); 3) Imitation and innovation (centralized procurement is expected to clear up, increase innovation, and traditional pharmaceutical companies will usher in new opportunities); 4) Traditional Chinese Medicine (the national policy supports the innovation of traditional Chinese medicine, and its performance is expected to maintain a good growth rate); 5) Medical devices (equipment updating, high-consumption innovation, low-consumption going to sea, etc.). Individual stocks can be concerned about: Baekje Shenzhou, Wuxi PharmaTech, China Resources Sanjiu and so on.The Hang Seng Index and Hang Seng Technology Index both fell more than 1%.Shenzhen accelerates to build a new generation of world-class automobile cities. The total output of automobiles this year is expected to exceed 2.8 million. Over the past hundred years, many well-known "automobile cities" have emerged continuously in the world automobile industry. As one of the earliest cities to develop new energy industry, Shenzhen has a solid foundation for industrial development, actively seizing the historical opportunity of global automobile industry reform and achieving "overtaking in corners" on new energy automobile tracks. In 2023, the output of new energy vehicles in the city reached 1.733 million, ranking first among cities in China. With the acceleration of intelligent process and the high coordination of industrial chain, a "new generation world-class automobile city" is accelerating in Shenzhen. (Shenzhen Special Zone Daily)
The main contract of the container transport index (European line) rose by 150.2 points in the day, and now it is reported at 2567.8 points, an increase of 6.21%.Look at the picture: The increased confidence of Japan's large-scale manufacturing industry indicates that the economic development is in line with the Bank of Japan's forecast. Before the Bank of Japan's policy meeting next week, the confidence of Japan's large-scale manufacturing industry has increased. According to the quarterly short-term report released by the Bank of Japan on Friday, the short-term survey index of Japan's large manufacturing industry rose slightly to 14 in December, with an estimated 13. The short-term survey index of large non-manufacturing industry decreased slightly from 34 to 33. Small businesses' confidence in manufacturing and service industries has also improved, although the outlook has slightly weakened or remained unchanged. The short-term report has attracted the attention of the Bank of Japan and is the last batch of major domestic data that will be carefully studied before the interest rate decision on December 19. This result shows that Japan's economic development is in line with the forecast of the Bank of Japan and is a condition for further interest rate hike. Compared with December, economists are more inclined to expect the Bank of Japan to take action in January next year, but still believe that the risk of raising interest rates next week is high.Shanghai Securities: The pharmaceutical and bio-industry is expected to further repair its performance and valuation. The Shanghai Securities Research Report pointed out that with the support of policies and the adjustment of the internal structure of the industry, the pharmaceutical and bio-industry is expected to further repair its performance and valuation. It is suggested to pay attention to five directions: 1) Innovative drugs (with strong national policy support, the payment terminal is expected to further improve and go to sea to occupy the global market); 2)CXO (the negative impact of the biosafety bill event has been eliminated, and the demand for orders in the superimposed interest rate reduction cycle has increased, which is expected to usher in a double repair of performance and valuation); 3) Imitation and innovation (centralized procurement is expected to clear up, increase innovation, and traditional pharmaceutical companies will usher in new opportunities); 4) Traditional Chinese Medicine (the national policy supports the innovation of traditional Chinese medicine, and its performance is expected to maintain a good growth rate); 5) Medical devices (equipment updating, high-consumption innovation, low-consumption going to sea, etc.). Individual stocks can be concerned about: Baekje Shenzhou, Wuxi PharmaTech, China Resources Sanjiu and so on.
Strategy guide
Strategy guide 12-14
Strategy guide
12-14
Strategy guide
12-14
Strategy guide 12-14
Strategy guide 12-14